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Cytomegalovirus Disease in Intestinal Transplantation 
H. Furukawa. R. Manez, S. Kusne, K. Abu-Elmagd, M. Green, G. Reyes, S. Todo, and T.E. Starzl 
OVER THE LAST 4 years. intestinal transplantation has become a feasible therapeutic option for patients 
with irreversible intestinal failure. l However. it has been 
shown that intestinal transplant recipients have a high 
incidence of cytomegalovirus (CMV) infection.1 In this 
study, we analyzed the incidence of CMV disease and 
CMV-related mortality after intestinal transplantation. 
MATERIALS AND METHODS 
From May 1990 to July 1994,62 patients (22 isolated intestine [I], 
29 liver and intestine [IlL], and 11 multivisceral [MV]) received 66 
intestinal allografts at our center. There were 28 adults and 34 
children. with ages ranging from 6 months to 58 years. Postopera-
tive immunosuppression was with tacrolimus (FK 506), steroids. 
and in selected cases azathioprine (AZA). Donor and recipient 
procedures are described elsewhere.! 
Tissue sampling for CMV was performed when it was clinically 
indicated. Invasive CMV disease was diagnosed by histopathologic 
findings and/or by isolation of the virus from tissue specimens. 
Tissue invasion was determined by detection of typical CMV 
inclusion bodies along with predominant neutrophilic infiltration 
and/or unequivocal immunoperoxidase staining of the virus. Isola-
tion of the virus was confirmed by either the shell vial technique or 
by standard culture. 
Forty-three of 62 recipients received gancyclovir prophylaxis (5 
mg/kg) twice a day for 2 to 3 weeks in children. and for 3 weeks to 
3 months in adults. followed by acyclovir for several months. CMV 
disease was treated by either gancyclovir (5 mg'kg twice a day). 
Foscarnet (tiO mg'kg three times a day), CMV immunoglobulin 
(100 mglkg every 2 weeks), or a combination of these agents. 
The elfect of CMV disease on patient and graft survival was 
studied. Chi·square. Kaplan-Meier. and log rank tests were used 
for statistical analysis. Statistical significance was achieved if the 
P value was less than .05. 
RESULTS 
Twenty-one (33%) of 62 recipients developed CMV disease 
after transplantation during a 2-month to 4-year follow-up 
period. CMV disease occurred a total of 49 times; to 
patients developed only one episode and II patients devel-
oped two to eight episodes of CMV disease. The type of 
CMV diseases seen were graft enteritis (41). native gas-
troduodenitis (3). hepatitis (2). pneumonitis (2). and reti-
nitis ( I). CMV disease occurred more frequently in adults 
(46%) than in children (20%) (P < .U5). This trend was 
more obvious in recurrent CMV disease (P < .UU5). The 
type of transplant procedure did not affect the frequency of 
CMV disease (I = 36%. ilL = 24%. MV = 45%). 
Table 1 shows the frequency of CMV disease compared 
to the CMV serology of the donor and recipient. No CMV 
disease was seen in CMV-seronegative patients receiving 
CMV -seronegative grafts. A statistical difference was found 
hetween this group and the other groups with the frequency 
Table 1. Frequency of CMV Disease and CMV SerolO9Y 
Donor/Recipient Follow-up Frequency of Frequency of Recurrent 
CMV Serology (mo) CMV Disease CMV Disease 
D-/R- 19 0126 (0) 0/26 (0) 
D-/R+ 16 5/12 (41 %) 1/12 (8%) 
D+/R- 12 10116 (62%) 7/16 (43%) 
O+/R+ 9 518 (62%) 2/8 (25%) 
of CMV disease (P < .0005). Five patients developed 
persistent CMV disease (>3 episodes in 1 year). Persistent 
CMV disease was seen only in CMV -seronegative adult 
isolated intestinal recipients who received CMV -seroposi-
tive grafts. The frequencies of CMV disease without (8 of 
19.42%) and with (13 of 43.30%) gancyclovir prophylaxis 
were similar. Gancyclovir prophylaxis was not effective in 
preventing CMV disease. 
Overall survival of patients with CMV disease was not 
significantly worse than patients without CMV disease: 
however, patients with CMV disease had significantly 
higher late (>3 months posttransplant) mortality (P = 
.0017) and graft loss (P = .0008) than patients without 
CMV disease. Death after 3 months was defined as late 
mortality. because the average first onset of CMV infection 
was 90.7 days. 
DISCUSSION 
Compared to other types of transplantation. infectious 
complications occur more frequently after intestinal trans-
plantation. because higher levels of immunosuppression are 
needed to prevent rejection.4 -t. Our results show that CMV 
disease occurs frequently after intestinal transplantation 
and is a major contributing factor in late mortality and graft 
loss. To prevent CMV disease. CMV-seropositive grafts 
should be avoided for isolated intestinal transplantation: 
however. this policy should not be applied to ilL and MV 
recipients. because they are in dire need of life-saving organ 
(liver) transplantation. Fortunately. we have not seen per-
sistent CMV disease in ilL or MV transplantation recipi-
ents. To reduce the incidence of CMV disease. improve-
ment of prophylactic antiviral therapies and avoidance of 
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heavy immunosuppression by using new strategies for re-
cipient immunomodulation are required. 
REFERENCES 
1. Todo S. Tzakis A. Reyes 1, et al: Transplant Proc 27:(this 
issue), 1995 
2. Manez R. Kusne S. Abu-E1magd K. et a1: Transplant Proc 
26: 1422. 1994 
FURUKAWA, MANEZ, KUSNE ET AL 
3. Furukawa H. Abu-E1magd K. Reyes 1. et al: Surg Technol Int 
2: 165, 1993 
4. Abu-Elmagd K. Todo S, Tzakis A. et al: Transplant Proc 
26: 1430. 1994 
5. Green M. Reyes 1. Tzakis A. et al: Transplant Proc 26: 14211. 
1994 
Ii. Kusne S. Manez R. Bonet H. et al: Transplant Proc 26: 16M2. 
1994 
lIT 
j J. 
R. 
1> 
W 
*- n 
* 1[!, 
Sl' 
:1 
t c: 
n 
0 
a 
( 
